Cellectar Bio’s Iopofosine Data Shows Favorable Safety Profile In Head & Neck Cancer

Vandana Singh , Benzinga Staff Writer  

{{following ? “Following” : “Follow”}}

September 22, 2021 12:27pm   155   Comments


Cellectar Biosciences Inc (NASDAQ: CLRB ) has  completed part A portion of a safety and tolerability study  of iopofosine I-131 (iopofosine) in combination with external beam radiation (EBRT) in relapsed or refractory head and neck cancer. 

Related: Cellectar Receives $2M NIH Grant For Rare Lymphoma Study .

The reduction in the amount or fractions (doses) of EBRT can potentially diminish the (number and severity of) adverse events associated with EBRT. 

Patients with head and neck cancer typically receive approximately 60-70 Grays (Gy) of EBRT given as 2 – 3 Gy daily doses over a six-week timeframe. 

Part B of the study will further assess the safety and potential benefits of iopofosine in combination with EBRT in a cohort of up to 24 patients.

Price Action: CLRB stock is up 2.58% at $0.98 during the market session on the last check Wednesday.

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.